http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2011152267-A1
Outgoing Links
Predicate | Object |
---|---|
assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_23622899a40ed163cd5bf570d6baf2a3 |
classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-131 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-133 |
classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-5375 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-167 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C215-24 |
filingDate | 2010-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ef614a5be73338794455d8cc75230d22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5182b990d3dd8f6c8080d355242b5e73 |
publicationDate | 2011-06-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber | US-2011152267-A1 |
titleOfInvention | Compositions and Methods for Treating Hyperproliferative Disorders |
abstract | A method of treating a hyperproliferative disorder in a subject in need of such treatment, comprising administering to said subject, in combination, a treatment effective amount of: (a) a ceramide-increasing retinoid such as fenretinide or a pharmaceutically acceptable salt thereof; and (b) at least one (and in certain embodiments at least two) compounds selected from the groups consisting of (i) a non-18 carbon chain length L-threo-sphinganine(s) or pharmaceuticeutically acceptable salt thereof, (ii) glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor(s), and (iii) sphingomyelin or dihydrosphingomyelin synthase inhibitor(s). Preferred L-threo-sphinganines are of carbon chain length 17 carbons, 19 carbons and 20 carbons. A preferred glucosylceramide or glucosyl(dihydro)ceramide synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred sphingomyelin or dihydrosphingomyelin synthesis inhibitor is D-threo-1-phenyl-2-palmitoylamino-3-morpholino-1-propanol. A preferred hyperproliferative disorder is brain cancers. |
isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11679157-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10758619-B2 |
priorityDate | 2009-11-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 305.